Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology innovations, has reported the grant of 95,000 restricted stock units and options to purchase 38,000 shares of common stock to 11 newly hired employees. These awards, approved by the Compensation Committee and granted under the company's 2022 Inducement Plan, have a grant date of October 1, 2024.
The restricted stock units vest over four years, with 25% vesting annually. Stock options also vest over four years, with 25% vesting after one year and the remainder in 36 monthly installments. The options have a ten-year term and an exercise price of $9.55 per share, matching Arcutis' closing stock price on October 1, 2024. This disclosure complies with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale focalizzata sulle innovazioni in immuno-dermatologia, ha annunciato l'assegnazione di 95.000 unità azionarie riservate e opzioni per l'acquisto di 38.000 azioni di azioni ordinarie a 11 nuovi dipendenti. Questi premi, approvati dal Comitato per la Compensazione e concessi nell'ambito del Piano di Induzione 2022 dell'azienda, hanno una data di assegnazione del 1 ottobre 2024.
Le unità azionarie riservate maturano in quattro anni, con il 25% che matura annualmente. Le opzioni azionarie maturano anch'esse in quattro anni, con il 25% che matura dopo un anno e il resto in 36 rate mensili. Le opzioni hanno un termine di dieci anni e un prezzo di esercizio di $9,55 per azione, corrispondente al prezzo di chiusura delle azioni di Arcutis del 1 ottobre 2024. Questa divulgazione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial enfocada en innovaciones en inmuno-dermatología, ha informado sobre la concesión de 95,000 unidades de acciones restringidas y opciones para comprar 38,000 acciones de acciones ordinarias a 11 empleados recién contratados. Estas recompensas, aprobadas por el Comité de Compensación y concedidas bajo el Plan de Inducción 2022 de la empresa, tienen una fecha de concesión del 1 de octubre de 2024.
Las unidades de acciones restringidas se consolidan durante cuatro años, con un 25% que se consolida anualmente. Las opciones de acciones también se consolidan durante cuatro años, con un 25% que se consolida después de un año y el resto en 36 cuotas mensuales. Las opciones tienen un plazo de diez años y un precio de ejercicio de $9.55 por acción, igualando el precio de cierre de las acciones de Arcutis el 1 de octubre de 2024. Esta divulgación cumple con la Regla de Cotización Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT)은 면역 피부과 혁신에 초점을 맞춘 상업 단계의 생명공학 회사로, 95,000개의 제한 주식 단위와 38,000주의 일반 주식을 구매할 수 있는 옵션을 11명의 신규 채용 직원에게 부여한 사실을 보고했습니다. 이러한 보상은 보상 위원회의 승인을 받았으며 회사의 2022 유치 계획에 따라 부여되었으며, 부여 날짜는 2024년 10월 1일입니다.
제한 주식 단위는 4년에 걸쳐 취득되며, 매년 25%가 취득됩니다. 주식 옵션도 4년에 걸쳐 취득되며, 1년 후 25%, 나머지는 36개월에 걸쳐 매월 취득됩니다. 옵션은 10년의 기한을 가지며 주당 $9.55의 행사 가격을 가지고 있으며, 이는 2024년 10월 1일 Arcutis의 종가와 일치합니다. 이 공개는 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise bio-pharmaceutique en phase commerciale axée sur les innovations en immuno-dermatologie, a rapporté l'octroi de 95 000 unités d'actions restreintes et d'options d'achat de 38 000 actions ordinaires à 11 nouveaux employés. Ces récompenses, approuvées par le Comité de Rémunération et accordées dans le cadre du Plan d'Induction 2022 de l'entreprise, ont une date d'octroi du 1er octobre 2024.
Les unités d'actions restreintes deviennent acquises sur quatre ans, avec 25 % devenant acquises chaque année. Les options d'achat d'actions deviennent également acquises sur quatre ans, avec 25 % devenant acquises après un an et le reste en 36 versements mensuels. Les options ont une duree de dix ans et un prix d'exercice de 9,55 $ par action, correspondant au prix de clôture des actions d'Arcutis le 1er octobre 2024. Cette divulgation est conforme à la règle de cotation Nasdaq 5635(c)(4).
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen in der Immunodermatologie konzentriert, hat die Gewährung von 95.000 eingeschränkten Aktieneinheiten und Optionen zum Kauf von 38.000 Aktien an 11 neu eingestellte Mitarbeiter bekannt gegeben. Diese Auszeichnungen, die vom Vergütungsausschuss genehmigt wurden und im Rahmen des Induktionsplans 2022 des Unternehmens vergeben wurden, haben ein Gewährungsdatum vom 1. Oktober 2024.
Die eingeschränkten Aktieneinheiten werden über vier Jahre fällig, wobei jährlich 25% fällig werden. Die Aktienoptionen werden ebenfalls über vier Jahre fällig, wobei 25% nach einem Jahr und der Rest in 36 monatlichen Raten fällig werden. Die Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 9,55 $ pro Aktie, der dem Schlusskurs von Arcutis am 1. Oktober 2024 entspricht. Diese Offenlegung erfüllt die Nasdaq-Listenregel 5635(c)(4).
- Arcutis is attracting new talent with 11 new hires
- The company is offering competitive stock-based compensation to retain employees
- Potential dilution of existing shareholders due to new stock grants and options
WESTLAKE VILLAGE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 95,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 38,000 shares of Arcutis’ common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates. The stock options vest over four years, with 25 percent vesting on the one-year anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Arcutis as of such vesting dates. The stock options have a ten-year term and an exercise price of
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
lvairavan@arcutis.com
This press release was published by a CLEAR® Verified individual.
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant to new employees?
What is the exercise price of the stock options granted by Arcutis Biotherapeutics (ARQT) on October 1, 2024?
How do the restricted stock units vest for new employees at Arcutis Biotherapeutics (ARQT)?
What is the vesting schedule for stock options granted to new employees by Arcutis Biotherapeutics (ARQT)?
